Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Overview of attention for article published in Arthritis Research & Therapy, November 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 2 news outlets

twitter: 2 X users

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 75 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Real-World Success Seen With Cimzia in RA

MedPage Today, 18 Nov 2015

Action Points Rapid and sustained clinical improvements were seen among a diverse group of patients with rheumatoid arthritis…

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Bioportfolio, 15 Nov 2015

IntroductionThis 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.